Pharmaceutically-Enhanced Reinforcement for Reduced Alcohol and Smoking — PERRAS  

Alcohol Use Disorder (AUD) Clinical Trial

Official title: Pharmaceutically-Enhanced Reinforcement for Reduced Alcohol and Smoking

Status Recruiting

Clinical Trial Summary

Using a randomized controlled trial (RCT), the goal of this study is to evaluate the ability of evidence based behavioral treatment (contingency management: CM) to significantly decrease alcohol use and cigarette smoking among treatment-seeking smokers with an alcohol use disorder (AUD) who have initiated pharmacotherapy (varenicline; VC) for smoking cessation.

Clinical Trial Description

This randomized, placebo-controlled trial to determine the effectiveness of contingency management for reducing alcohol use and cigarette smoking among adults who want to quit or reduce their co-addiction. Contingency management is a powerful and cost-effective technique that has been used successfully for decades to promote abstinence from benzodiazepines, cocaine, tobacco, etc. Contingency management, and a non-contingent control condition will be used combined with varenicline (VC) and manualized counseling in the form of module videos. ;

Related Conditions & MeSH terms

• Alcohol Drinking
• Alcohol Use Disorder (AUD)
• Alcoholism
• Disease
• Nicotine Use Disorder
• Tobacco Use Disorder

• NCT number: NCT05181891
• Study type: Interventional
• Source: Washington State University
• Contact: Abigail Bowen, MS
• Phone: (425) 736-1354
• Email: abigail.bowen@wsu.edu
• Status: Recruiting
• Phase: Phase 2
• Start date: July 11, 2022
• Completion date: May 1, 2026